Ireland
--:--IST
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing
Clinical Trials in Portugal / NCT05580315
Recruiting Observational

EPOS Discoid Meniscus (DiMe) Project

NCT05580315 · tracked via the Priya Life Science Portugal tracker
Sponsor
University of Milano Bicocca
Phase
Observational
Started
2022-09-08
Last updated
2025-07-25

Condition(s) studied

Discoid Meniscus of Knee

Study summary

The aims of this Discoid Meniscus (DiMe) project are to analyze DM tears characteristics in the pediatric European population to describe current treatment options in symptomatic DM, and to evaluate clinical outcomes. To reach these objectives, a prospective database including symptomatic DM and variables associated with DM characteristics, type of tears, treatment, imaging, and clinical follow-up will be implemented. Data collection platform will provide future studies to understand the best treatment option for skeletally immature patient with symptomatic DM according to their history and lesion characteristics.

Eligibility

Sex
ALL
Min age
1 Year
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * symptomatic DM confirmed by a senior orthopedic surgeon based on physical examination and MRI * age less than eighteen years * informed consent freely granted and acquired before the start of the study from legal representative Exclusion Criteria: * concomitant or previous knee surgeries * concomitant ligament knee injury that requires a surgical treatment * concomitant fractures * inflammatory or arthritic diseases.

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Universitair Ziekenhuis Leuven Belgium Not Yet Recruiting
Oulu University Hospital, Oulu Finland Not Yet Recruiting
CHU Grenoble Grenoble France Not Yet Recruiting
Clinique Rive Gauche Toulouse France Not Yet Recruiting
Department of Orthopaedic Surgery, Hôpital des Enfants, CHU de Toulouse Toulouse France Not Yet Recruiting
Policlinico San Pietro Bergamo BG Not Yet Recruiting
ASST Monza - Ospedale San Gerardo Monza Italy Recruiting
Department of Pediatric Orthopaedics, Hospital Pediátrico de -Coimbra Coimbra Portugal Not Yet Recruiting
Hospital Cuf Descobertas Lisbon Portugal Not Yet Recruiting
Centre hospitalier universitaire vaudois (CHUV) Lausanne Switzerland Not Yet Recruiting
London Children's Hospital London United Kingdom Not Yet Recruiting
SHEFFIELD CHILDREN'S NHS NHS Foundation Trust, Sheffield United Kingdom Not Yet Recruiting

More University of Milano Bicocca trials in Portugal

International CIPN Assessment and Validation Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05580315 on ClinicalTrials.gov ↗ ← All trials in Portugal